Chemical structure of Flucloxacillin.
Find information on thousands of medical conditions and prescription drugs.

Flucloxacillin

Flucloxacillin (INN) or floxacillin (USAN) is a narrow spectrum beta-lactam antibiotic. It is used to treat infections caused by susceptible Gram-positive bacteria. Notably, it is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins. It is very similar to dicloxacillin and these two agents are considered interchangeable. Flucloxacillin is available under a variety of trade names including Flopen (CSL) and Floxapen (GSK). more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Mode of action

Like other β-lactam antibiotics, flucloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria.

Medicinal chemistry

Flucloxacillin is insensitive to beta-lactamase (also known as penicillinase) enzymes secreted by many penicillin-resistant bacteria. The presence of the isoxazolyl group on the side chain of the penicillin nucleus facilitates the β-lactamase resistance, since they are relatively intolerant of side-chain steric hindrance. Thus it is able to bind to penicillin binding proteins (PBPs) and inhibit peptidoglycan crosslinking, but is not bound by or inactivated by β-lactamases.

Clinical use

Flucloxacillin is more acid-stable than many other penicillins and can be given orally, in addition to parenteral routes. However, like methicillin, it is less potent than benzylpenicillin against non-β-lactamase-producing Gram-positive bacteria.

Flucloxacillin has similar pharmacokinetics, antibacterial activity and indications to dicloxacillin and the two agents are considered interchangeable. It is believed to have higher incidence of severe hepatic adverse effects than dicloxacillin, but a lower incidence of renal adverse effects. (Rossi, 2006)

Available forms

Flucloxacillin is commercially available as the sodium salt flucloxacillin sodium, in capsules (250 or 500 mg), oral suspensions (125 mg/5 mL or 250 mg/5 mL), and injections (powder for reconstitution, 250, 500 and 1000 mg per vial).

Indications

Flucloxacillin is indicated for the treatment of infections caused by susceptible bacteria. Specific approved indications include: (Joint Formulary Committee, 2005; Rossi, 2006)

  • Staphylococcal skin infections and cellulitis – including impetigo, otitis externa, folliculitis, boils, carbuncles, and mastitis
  • Pneumonia (adjunct)
  • Osteomyelitis, septic arthritis
  • Septicaemia
  • Empirical treatment for endocarditis
  • Surgical prophylaxis

Flucloxacillin has relatively poor activity, as noted above, against non-β-lactamase-producing bacteria including Streptococcus pyogenes. Therefore empirical therapy for significant cellulitis often involves dual-therapy to cover both staphylococci and streptococci, using either penicillin or ampicillin in addition to flucloxacillin. The latter is available as a standardardised combination preparation co-fluampicil (flucloxacillin+ampicillin).

Precautions/contraindications

Flucloxacillin is contraindicated in those with a previous history of allergy to penicillins, cephalosporins or carbapenems. It should also not be used in the eye, or those with a history of cholestatic hepatitis associated with the use of dicloxacillin or flucloxacillin. (Rossi, 2006)

Read more at Wikipedia.org


[List your site here Free!]


Is there a role for extended antibiotic therapy in a two-stage revision of the infected knee arthroplasty?
From Journal of Bone and Joint Surgery, 2/1/05 by Hoad-Reddick, D A

All major studies have incorporated the use of prolonged courses of parenteral or oral antibiotic therapy in the management of two-stage revision of an infected total knee arthroplasty. We present a series of 59 consecutive patients, all with microbiologicallyproven deep infection of a total knee arthroplasty, in whom a prolonged course of antibiotic therapy was not routinely used. The mean follow-up was 56.4 months (24 to 114).

Of the 38 patients who underwent a staged exchange, infection was successfully eradicated in 34 (89%) but recurrent or persistent infection was present in four (11%). Our rate of cure for infection is similar to that reported elsewhere. We conclude that a prolonged course of antibiotic therapy seems not to alter the incidence of recurrent or persistent infection. The costs of the administration of antibiotics are high and such a regime may be unnecessary.

Deep infection remains a difficult problem after knee replacement surgery and rates between 0.5% and 2% have been reported.1-3 Increased rates of infection are encountered in knees which have undergone many operations and in patients with other medical comorbidities.4,5 Treatment of an infected knee arthroplasty is controversial with many protocols being described. Each has its advocates with options which include arthroscopic wash-out,6 open debridement with exchange of polyethylene and a staged exchange of components. The last approach may include the use of antibiotic spacers, with subsequent reimplantation when soft tissues permit and infection appears to have been eradicated. This two-stage approach is perhaps the method of choice with reported rates of control of infection in the region of 90%.9 All major studies reported to date have involved the long-term administration of antibiotics between the stages,9-11and more recent series have also included the use of antibiotic impregnation of the cement spacer.10,12-14 Antibiotics are often delivered intravenously which frequently requires a lengthy inpatient stay and placement of a central venous catheter. The costs both to the patient and the health care facility are high.15,16

In our unit, we use a two-stage approach with radical debridement, the insertion of an antibiotic-impregnated cement spacer and antibiotic-loaded beads at the first stage. Prolonged courses of antibiotics have not been routinely used. We now report an analysis of all the patients treated by a two-stage reconstruction for infection of a total knee arthroplasty under the care of the senior author (IS).

Patients and Methods

Between 1992 and 2001, a two-stage reconstruction in 59 patients with suspected deep infection of a total knee arthroplasty was undertaken. These patients have been prospectively followed up every year both clinically and radiologically according to our policy. We defined infection as multiple, positive microbiological samples obtained either at aspiration or at first-stage debridement. No microbiological evidence of infection was identified in six patients and these were therefore excluded, leaving 53 with definite infection.

There were 27 women and 32 men with a mean age at presentation of 70.6 years (34.8 to 87.1). Comorbidity was common, with nine patients having diabetes mellitus. Two required dialysis for chronic renal failure and one had hypophosphataemic rickets. Six had rheumatoid arthritis, one had psoriatic arthritis and the remainder had osteoarthritis.

Aspiration was performed on all patients before the first-stage debridement and the results were interpreted by a microbiologist (PN) with an interest in prosthetic infection. The antibiotics were stopped at least two weeks before the aspiration.

At the first stage, the antibiotics were withheld until multiple tissue specimens had been taken. After removal of the components and all cement, the bone and soft tissues were radically debrided. Restoration of the soft-tissue envelope had a high priority, with plastic surgery being undertaken at the time of the first stage when necessary.

In order to provide stability, maintain the joint space and supply antibiotics, a polymethylmethacrylate spacer was prepared at the time of surgery. Additional antibiotics were added to the cement as indicated by the culture results at pre-operative aspiration. Increased local elution of antibiotics was achieved by fashioning cement beads, again with additional antibiotics, a method which has been shown to give higher concentrations of antibiotic locally than are achieved by the administration of intravenous antibiotics.17 The customised cement beads and spacer were tailored to the microbiological findings. When either vancomycin or gentamicin was indicated, 2.0 g of vancomycin or 1.0 g of gentamicin were added to each 40 g mix of Palacos R cement (Schering Plough Ltd, Welwyn Garden City, UK). When required, additional stability was obtained by the use of an intramedullary nail of narrow diameter coated in cement.

A broad-spectrum antibiotic, typically cefuroxime (1.5 g at induction and two further doses of 750 mg at eight and 16 hours post-operatively), was given intravenously as surgical prophylaxis. No additional oral or intravenous antibiotics were given routinely. The patients were mobilised, weight-bearing as tolerated, and were discharged home when their wound was dry and they had adequate mobility.

Outpatient monitoring included clinical examination and assessment of inflammatory markers. When the soft tissues were quiescent and serological markers were satisfactory (CRP

At re-implantation multiple specimens were again collected for microbiological analysis and the same regime of antibiotic prophylaxis was used. The results of cultures from the first stage determined what antibiotics, if any, were added to the cement which was used for the fixation of the components.

The mean number of surgical procedures performed before presentation to our unit was 1.9 (1 to 8). Eleven patients had already undergone multiple revision procedures, with a mean of four procedures (2 to 8).

Twenty-nine patients (49%) presented with open, purulent wounds, discharging sinuses or frank formation of an abscess. In order to achieve a stable, well-vascularised softtissue envelope, nine patients required plastic surgery.

Results

Thirty-nine patients underwent a staged re-implantation of their total knee arthroplasty. A formal two-stage arthrodesis was performed in five in whom the quality of the softtissue envelope was considered to be too poor for prosthetic reimplantation, despite having had plastic surgery, or when the extensor mechanism was found to be inadequate. Nine had a debridement and implantation of a cement spacer for infection but were either considered to be too unfit for, or declined, further surgical reconstruction. One underwent an above-knee amputation after a vascular injury which occurred during their second-stage re-implantation and has therefore been excluded from the results relating to infection. A total of six patients who had further surgery, reconstruction or arthrodesis, required a further debridement before reimplantation. Two of these needed a total of three debridements before definitive re-implantation. The median interval between the stages was 24 weeks (4 to 64).

The mean follow-up after the second stage was 56.4 months (24 to 114). A total of 44 patients underwent a staged procedure. All had microbiologically-confirmed deep infection. In 30 (68%) a single organism was identified (Table I), whereas in the remaining 14 (32%) there was more than one infecting organism. Three of these patients were infected by three different organisms. The most commonly encountered organism in this group was coagulasenegative staphylococcus (CNS). This was isolated in 11 of the 14 patients. The incidence of sinuses was also high in this group (eight of 14 patients). No organisms were grown from second-stage samples in 37 patients (84%) but seven (16%) had positive samples from the second stage (Table II).

Of the 38 patients, one being excluded as a consequence of above-knee amputation, who underwent a staged exchange, infection was successfully eradicated in 34 (89%) but recurrent or persistent infection appeared in four (11%) (Table III). These patients could be divided into two groups, those infected by a single organism and those with an infection which was caused by more than one organism. Twenty-five (96%) of the 26 patients who were infected by a single organism were treated successfully by this regime. In the 13 patients with more than one organism, recurrent or persistent infection was seen in three. This gave a rate of success for the eradication of infection of 77%.

Of the five patients who underwent a staged arthrodesis, all had negative cultures at the time of their fusion. We achieved a successful fusion, with eradication of infection, in four (80%). The remaining patient, who required a local gastrocnemius flap, had a loose intramedullary nail on review. The previous infection was caused by a species of Enterococcus. A repeat aspiration isolated CNS and further surgery is planned.

Discussion

This is a consecutive series of microbiologically-confirmed infected knee arthroplasties managed by a single surgeon. As with other series, multiple operations and medical comorbidities were commonplace. Other series of similar patients have reported comparable results for the eradication of infection but all have used long-term antibiotic therapy, either oral or intravenous, which has ranged in duration from six weeks to 16 months. In our series, long-term antibiotic therapy was not routinely used. The mean duration of intravenous therapy of 4.64 days (1 to 7). Only three patients in the successful groups required further courses of oral antibiotics. One patient needed a course of flucloxacillin for six weeks between the first and second stages in order to provide antibiotic cover for plastic surgery (tissue expansion). Two patients took oral ampicillin after their second-stage reimplantation, for five days and six weeks, respectively since their original infecting organisms included a high-level gentamicin-resistant Enterococcus.

Repeat debridement was required in six of the 44 patients. Two required a total of three debridements before re-implantation. A high incidence of pre-operative sinuses was seen in these patients; four sinuses in six patients. Infection by multiple organisms was associated with a poor outcome (Table III).

We, therefore, suggest that prolonged courses of antibiotics may be unnecessary provided that a rigorous debridement is performed and microbiological advice is followed regarding the addition of appropriate antibiotics to the cement at the appropriate stages. We use custom-made antibiotic beads to deliver a high local concentration of antibiotic to the bone and soft tissues. These are used in addition to an antibiotic-impregnated cement spacer. The available surface area of the beads is greater than that of a spacer and therefore allows a larger dose of antibiotic to be eluted from them. By employing this protocol we have shown comparable results with those of other series, all of which used prolonged courses of antibiotic therapy in addition to surgical debridement and antibiotic-loaded cement spacers.

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

1. Gill GS, Mills DM. Long-term follow-up evaluation of 1000 consecutive cemented total knee arthroplasties. Clin Orthop 1991;273:66-76.

2. Bengtson S, Knutson K. The infected knee arthroplasty: a 6-year follow-up of 357 cases- Acta Orthop Scand 1991;62:301 -11.

3. Rand JA, Fitzgerald RH Jr. Diagnosis and management of the infected total knee arthroplasty Orthop Clin North Am 1989:20:201-10.

4. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee arthroplasty: risk factors and treatment in sixty-seven cases. J Bone Joint Surg [Am] 1990;72-A:878-83.

5. Wymenga AB, van Horn HJ, Theeuwes A, Muytjens HL, Sloof TJ. Perioperative factors associated with septic arthritis after arthroplasty: prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 1992;63:665-71.

6. Dixon P, Parish EN, Cross MJ. Arthroscopic debridement in the treatment of the infected total knee replacement. J Bone Joint Surg [Br]2004;86-B:39-42.

7. Schoifet SD, Morrey BF. Treatment of infection after total knee arthroplasty by debridement with retention of the components. J Bone Joint Surg [Am] 1990;72-A: 1383-90.

8. Scott IR, Stockley I, Gerry CJ. Exchange arthroplasty for infected knee replacements: a new two-stage method. J Bone Joint Surg [Br]1993:75-6:28-31.

9. Hanssen AD. Managing the infected knee: as good as it gets. J Arthmplasty 2002;17 (Suppl 1):98-101.

10. Whiteside LA. Treatment of infected total knee arthroplasty. Clin Orthop 1994;299:169-72.

11. Wilde AH, Ruth JT. Two-stage reimplantation in infected total knee arthroplasty. Clin Orthop 1988;236:23-35.

12. Haddad FS, Masri BA, Campbell D, et al. The PROSTALAC functional spacer in two-stage revision for infected knee replacements: prosthesis of antibiotic-loaded acrylic cement. J Bone Joint Surg [Br] 2000;82-B:807-12.

13. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Instr Course Lea 1999:48:111-22.

14. Jones N, Berendt AR. Principles and practice of antimicrobial therapy of the infected joint replacement. Curr Orthop 2000; 14:250-6.

15. Sculco TP. The economic impact of infected total joint arthroplasty. Instr Course Lect 1993:42:349-51.

16. Barrack RL. Economics of the infected total knee replacement Orthopedics 1996:19:780-2.

17. Wininger OA, Fass RJ. Antibiotic-impregnated cement and beads for orthopaedic infections. Antimicmb Agents Chemother 1996:40:2675-9.

D. A. Hoad-Reddick, C. R. Evans, P. Norman, I. Stockley

From Sheffield Teaching Hospitals Trust, Sheffield, England

* D. A. Hoad-Reddick, MBChB, FRCS(Tr & Orth), Cavendish Hip Fellow

* I. Stockley, MD, FRCS, Consultant Orthopaedic Surgeon

Department of Orthopaedic Surgery

* P. Norman, MA, MSc, MB, FRCPath, Consultant Microbiologist

Department of Microbiology Sheffield Teaching Hospitals Trust, Herries Road, Sheffield S57AU, UK.

* C. R. Evans, MBChB, FRCS (Tr & Orth), Consultant Orthopaedic Surgeon

The Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust, Gobowen, Oswestry, Shropshire SY10 7AG, UK.

Correspondence should be sent to Mr I. Stockley; e-mail: ian.stockley@sth.nhs.uk

©2005 British Editorial Society of Bone and Joint Surgery

doi:10.1302/0301-620X.87B2. 15640 $2.00

J Bone Joint Surg [Br] 2005;87-B:171-4.

Received 77 May 2004; Accepted 27 July 2004

Copyright British Editorial Society of Bone & Joint Surgery Feb 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Flucloxacillin
Home Contact Resources Exchange Links ebay